How do you contextualize the stage 1 results from the PRESERVE-003 trial within the current treatment landscape for patients with squamous NSCLC who have progressed on PDL-1 therapy?

The PRESERVE-003 trial evaluated gotistobart, a novel CTLA-4 antibody, compared to docetaxel in participants with squamous cell NSCLC who had tumor progression on prior platinum-based doublet chemotherapy and immunotherapy. The trial was conducted in 2 stages, and results from the first stage are av...